Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Affiliation

Department of Oncology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 3J1, Canada. Electronic address: [Email]

Abstract

With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in some patients. In this retrospective analysis of EGFR mutation-positive (Del19/L858R) patients receiving first-line afatinib in LUX-Lung 3, 6, and 7, we assessed uptake of, and outcomes following, subsequent therapies including the third-generation EGFR TKI, osimertinib.

Keywords

Afatinib,Non-small cell lung cancer,Osimertinib,

OUR Recent Articles